Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veliparib (Primary) ; Cisplatin; Etoposide
  • Indications Carcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 05 Dec 2018 Primary endpoint has been met. (Progression-free survival rate (stratified)), as reported in an article published in the Journal of Clinical Oncology
    • 05 Dec 2018 Primary endpoint has not been met. (Progression-free survival rate (Phase II)), as reported in an article published in the Journal of Clinical Oncology
    • 05 Dec 2018 Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top